Cite

HARVARD Citation

    Blevins, T. et al. (2017). Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgraduate medicine. 129 (1), pp. 159-168. [Online]. 
  
Back to record